The aim of this study was to evaluate the effect of different types of pharmacotherapy on pupillometric parameters in PD patients. Dopamine was shown to induce mydriasis by excitation of alpha-adrenergic receptors at the dilator pupillae muscle. Pupil diameter may thus serve as an indirect measure of peripheral dopaminergic activity. A total of 63 PD patients were treated with different types of dopaminergic pharmacotherapy. Pupil examination was performed before the first application of dopaminergic pharmacotherapy and then after one year of treatment in the OFF state and in the ON state. There were significant differences in pupillometric parameters obtained at baseline and at year 1 OFF and ON. The pupillometry did not differ among type of used pharmacotherapy in most pupillometric parameters. Two-way ANOVA confirmed the significant effect of visit in the pupillometric parameters MAX and MIN, but did not confirm the significant effect treatment between groups of patients with L-DOPA pharmacotherapy and with dopamine agonist. Linear regression analysis showed significant dose-response relationships between the most pupillometric parameters and L-DOPA equivalent doses in the patients treated with L-DOPA and dopamine agonist. In conclusion, this analysis does not confirm a differential pupillary response according to type of pharmacotherapy in PD patients.

Department of Neurology Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague 121 08 Czech Republic

Institute of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

See more in PubMed

Poewe, W. et al. Parkinson disease. PubMed

Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J. & Stefanis, L. Pathological roles of alpha-synuclein in neurological disorders. PubMed

LeWitt, P. A. & Fahn, S. Levodopa therapy for Parkinson disease: A look backward and forward. PubMed

Cenci, M. A. Presynaptic mechanisms of l-DOPA-Induced dyskinesia: the findings, the debate, and the therapeutic implications. PubMed PMC

Poewe, W. & Antonini, A. Novel formulations and modes of delivery of Levodopa. PubMed

Seppi, K. et al. The movement disorder society Evidence-Based medicine review update: treatments for the non-motor symptoms of parkinson’s disease. PubMed PMC

Spiers, A. S., Calne, D. B., Vakil, S. D. & French, T. M. Action of thymoxamine on mydriasis induced by Levodopa and dopamine. PubMed PMC

Shannon, R. P., Mead, A. & Sears, M. L. The effect of dopamine on the intraocular pressure and pupil of the rabbit eye. PubMed

Velasco, M. & Luchsinger, A. Dopamine: Pharmacologic and therapeutic aspects. PubMed

Gordan, R., Gwathmey, J. K. & Xie, L. H. Autonomic and endocrine control of cardiovascular function. PubMed PMC

Jain, S. Multi-organ autonomic dysfunction in Parkinson disease. PubMed PMC

You, S., Hong, J. H. & Yoo, J. Analysis of pupillometer results according to disease stage in patients with parkinson’s disease. PubMed PMC

Fotiou, D. F. et al. Cholinergic deficiency in alzheimer’s and parkinson’s disease: evaluation with pupillometry. PubMed

Giza, E., Fotiou, D., Bostantjopoulou, S., Katsarou, Z. & Karlovasitou, A. Pupil light reflex in parkinson’s disease: evaluation with pupillometry. PubMed

Group, P. D. M. C. et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with Levodopa as initial treatment for parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. PubMed

Giza, E. et al. Pupillometry and I-DaTSCAN imaging in parkinson’s disease: A comparison study. PubMed

Bartosova, O. et al. Pupillometry as an indicator of L-DOPA dosages in parkinson’s disease patients. PubMed

Fahn, S. et al. Levodopa and the progression of parkinson’s disease. PubMed

Chen, Z. C., Li, G. L. & Liu, J. Autonomic dysfunction in Parkinson’s disease: Implications for pathophysiology, diagnosis, and treatment. PubMed

Tsitsi, P. et al. Pupil light reflex dynamics in Parkinson’s disease. PubMed PMC

Armstrong, R. A. Oculo-Visual dysfunction in parkinson’s disease. PubMed PMC

Iscan, D., Türkoglu, C. & Arslan, E. Evaluation of autonomic involvement in Parkinson’s disease using pupillometry. PubMed PMC

Dawidziuk, A. et al. Can the Pupillary Light Reflex and Pupillary Unrest Be Used as Biomarkers of Parkinson’s Disease? A Systematic Review and Meta-Analysis. PubMed PMC

Tekin, K. et al. Static and dynamic pupillometry data of healthy individuals. PubMed

Winn, B., Whitaker, D., Elliott, D. B. & Phillips, N. J. Factors affecting Light-Adapted pupil size in normal Human-Subjects. PubMed

Guillon, M. et al. The effects of age, refractive status, and luminance on pupil size. PubMed PMC

Dusek, P. et al. Clinical characteristics of newly diagnosed parkinson’s disease patients included in the longitudinal BIO-PD study.

Postuma, R. B. et al. MDS clinical diagnostic criteria for parkinson’s disease. PubMed

Hsu, A., Yao, H. M., Gupta, S. & Modi, N. B. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet), sustained-release carbidopa-levodopa (Sinemet CR), and carbidopa-levodopa-entacapone (Stalevo). PubMed PMC

Goetz, C. G. et al. Movement disorder Society-sponsored revision of the unified parkinson’s disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. PubMed

Kopecek, M. et al. Montreal cognitive assessment (MoCA): normative data for old and very old Czech adults. PubMed

Nasreddine, Z. S. et al. The Montreal cognitive assessment, moca: a brief screening tool for mild cognitive impairment. PubMed

Parkinson´s Measurement, L. E. D. & Calculator (2023). https://www.parkinsonsmeasurement.org/toolBox/levodopaEquivalentDose.htm. Accessed 30 December 2023.

Matouskova, O., Slanar, O., Chytil, L. & Perlik, F. [Infrared pupilometry as a biomarker of drug effects]. PubMed